Methylation profiling in acute myeloid leukemia.

Blood
Minoru ToyotaJean-Pierre Issa

Abstract

Aberrant methylation of multiple CpG islands has been described in acute myeloid leukemia (AML), but it is not known whether these are independent events or whether they reflect specific methylation defects in a subset of cases. To study this issue, the methylation status of 14 promoter-associated CpG islands was analyzed in 36 cases of AML previously characterized for estrogen-receptor methylation (ERM). Cases with methylation density of 10% or greater were considered positive. Seventeen cases (47%) were ERM(+) while 19 cases were ERM(-). Hypermethylation of any of the following, p15, p16, CACNA1G, MINT1, MINT2, MDR1, THBS1, and PTC1 (2 promoters), was relatively infrequent (6% to 31% of patients). For each of these CpG islands, the methylation density was positively correlated with ERM density (rank order correlation coefficients, 0.32-0.59; 2-tailed P < or = .058 for each gene). Hypermethylation of MYOD1, PITX2, GPR37, and SDC4 was frequently found in AML (47% to 64% of patients). For each of these genes as well, methylation density was positively correlated with ERM density (correlation coefficients 0.43 to 0.69, P < or = .0087 for each gene). MLH1 was unmethylated in all cases. Hypermethylation of p15, MDR1, and SDC4 corre...Continue Reading

References

Dec 8, 1995·Science·D P Barlow
Aug 1, 1994·American Journal of Hematology·D TreccaA Neri
Aug 11, 1994·Nucleic Acids Research·S J ClarkM Frommer
Jun 15, 1997·Nucleic Acids Research·Z Xiong, P W Laird
Apr 7, 1998·Leukemia·J R MelkiS J Clark
Oct 17, 1998·Eye·C F Inglehearn
Jan 14, 1999·Journal of Hypertension·F C Luft
Feb 3, 1999·Annual Review of Genetics·J D Rowley
Feb 9, 1999·Human Molecular Genetics·T H HuangD E Laux
Feb 13, 1999·Nature Genetics·P A Jones, P W Laird
Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·M ToyotaJ P Issa
Oct 16, 1999·Science·A P Wolffe, M A Matzke
Dec 10, 1999·Critical Reviews in Oncology/hematology·J P Issa

❮ Previous
Next ❯

Citations

Oct 19, 2005·Annals of Hematology·Oliver GalmRainhardt Osieka
Jun 26, 2013·Cancer Causes & Control : CCC·Chun ChaoMary Helen Black
Aug 7, 2002·Current Oncology Reports·Francis J Giles
Jan 24, 2006·Blood Reviews·Oliver GalmStephen B Baylin
Jun 2, 2005·Leukemia Research·Hui YangGuillermo Garcia-Manero
Oct 22, 2003·Experimental Cell Research·Emma K Baker, Assam El-Osta
Jul 27, 2002·Cancer Letters·Laura J Rush, Christoph Plass
Feb 5, 2003·Cancer Letters·Kenneth P Nephew, Tim Hui-Ming Huang
Aug 23, 2002·Seminars in Cancer Biology·John R Melki, Susan J Clark
Oct 31, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Giuseppe LeoneMichael Lübbert
Oct 31, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Manel Esteller
Dec 13, 2005·Nature Clinical Practice. Oncology·Lewis R Silverman, Ghulam J Mufti
Dec 2, 2004·Nature Reviews. Cancer·Jean-Pierre Issa
Jul 28, 2006·Cold Spring Harbor Symposia on Quantitative Biology·J G Herman
Mar 23, 2011·Biochemistry. Biokhimii︠a︡·E V Chetverina, A B Chetverin
Aug 19, 2011·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Félix Recillas-TargaErnesto Soto-Reyes
Nov 21, 2007·Hematology·Guillermo Garcia-Manero
Oct 1, 2005·Blood·Aurélie KieusseianAnne Dubart-Kupperschmitt
Oct 4, 2008·Blood·Ying JiangJaroslaw P Maciejewski
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lanlan ShenJean-Pierre J Issa
Sep 15, 2009·PloS One·Jose I Martin-SuberoReiner Siebert
Oct 16, 2004·International Journal of Hematology·Tomohiro Kinoshita
Oct 16, 2004·International Journal of Hematology·Oliver Galm, Manel Esteller
Mar 25, 2008·Therapeutics and Clinical Risk Management·Kavita Raj, Ghulam J Mufti

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.